Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Investigation

• Publication date

  2005-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI23373PMID 15696196PMCID PMC546459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.

  2011cited by this paper
• T cell memory.

  2006cited by this paper
• Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon-γ ELISPOT Assays for Patient Immune Monitoring

  2004cited by this paper
• Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

  2004cited by this paper
• LIGHTing the way for tumor immunity

  2004cited by this paper
• Priming of naive T cells inside tumors leads to eradication of established tumors

  2004cited by this paper
• Immunotherapeutic uses of CpG oligodeoxynucleotides

  2004cited by this paper
• Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination

  2004cited by this paper
• CpG-matured Murine Plasmacytoid Dendritic Cells Are Capable of In Vivo Priming of Functional CD8 T Cell Responses to Endogenous but Not Exogenous Antigens

  2004cited by this paper
• Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

  2004cited by this paper
• Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

  2004cited by this paper
• Tumour immunology.

  2003cited by this paper
• A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

  2003cited by this paper
• Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells

  2003cited by this paper
• T cell memory.

  2003cited by this paper
• Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo

  2003cited by this paper
• Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

  2003influential reference
• A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

  2003cited by this paper
• Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

  2003cited by this paper
• Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions.

  2003influential reference
• Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

  2003cited by this paper
• CpG motifs in bacterial DNA and their immune effects.

  2002cited by this paper
• CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide

  2002cited by this paper
• T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

  2002cited by this paper
• Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma

  2002influential reference
• Toll-like receptors: critical proteins linking innate and acquired immunity

  2001cited by this paper
• Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens

  2001cited by this paper
• Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

  2001cited by this paper
• Kinetics of TCR Use in Response to Repeated Epitope-Specific Immunization

  2001cited by this paper
• Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells1

  2001cited by this paper
• Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs1 2

  2001cited by this paper
• Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs

  2001cited by this paper
• Repeated Administration of Cytosine-Phosphorothiolated Guanine-Containing Oligonucleotides Together with Peptide/Protein Immunization Results in Enhanced CTL Responses with Anti-Tumor Activity1

  2000cited by this paper
• Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1

  2000cited by this paper
• IFN-α and IFN-β: a link between immune memory and chronic inflammation

  2000cited by this paper
• IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation.

  2000cited by this paper
• CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.

  2000cited by this paper
• CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell Responses1

  2000cited by this paper
• A Toll-like receptor recognizes bacterial DNA

  2000cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines

  1999cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis.

  1999cited by this paper
• Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

  1999cited by this paper
• High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

  1999cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

  1997cited by this paper
• CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants

  1997cited by this paper
• Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

  1997cited by this paper
• Innate immunity: impact on the adaptive immune response.

  1997cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996cited by this paper
• Subversion of the immune system by pathogens.

  1994cited by this paper
• Programmed cell death and extrathymic reduction of Vβ8+CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B

  1991cited by this paper
• The dendritic cell system and its role in immunogenicity.

  1991cited by this paper
• Approaching the asymptote? Evolution and revolution in immunology.

  1989cited by this paper

• Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.

  2026cites this paper
• Research and Clinical Progress of Therapeutic Tumor Vaccines

  2025cites this paper
• Hematoporphyrin-Modified Dendrimers Combined Immunoadjuvants for Enhanced Photoimmunotherapy of Colorectal Cancer.

  2025cites this paper
• Antibody Responses to Melanoma Helper Peptide Vaccines May Enhance Antigen Opsonization Through Formation of Immune Complexes and are Modulated by Vaccine Adjuvants

  2025cites this paper
• Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials

  2025cites this paper
• Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers

  2025cites this paper
• Cholesterol-modified peptide nanomicelles as a promising platform for cancer therapy: A review.

  2025cites this paper
• A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine

  2025cites this paper
• Rational design of adjuvants boosts cancer vaccines.

  2024cites this paper
• Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

  2024cites this paper
• Orchestrated codelivery of peptide antigen and adjuvant to antigen-presenting cells by using an engineered chimeric peptide enhances antitumor T-cell immunity.

  2024cites this paper
• An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

  2024cites this paper
• Oxidized Melanoma Antigens Promote Activation and Proliferation of Cytotoxic T‐Cell Subpopulations

  2024cites this paper
• Complexing CpG adjuvants with cationic liposomes enhances vaccine-induced formation of liver TRM cells.

  2023cites this paper
• Linking Viral DNA to Endosomal Innate Immune Recognition.

  2023cites this paper
• The immune enhancement effect of CpG-ODNs on the vaccine of inactivated Vibrio harveyi in tiger puffer (Takifugu rubripes)

  2023cites this paper
• Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy

  2023cites this paper
• Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment

  2023cites this paper
• A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection.

  2023cites this paper
• Adjuvant physiochemistry and advanced nanotechnology for vaccine development.

  2023cites this paper
• Toll-like receptor agonists as cancer vaccine adjuvants

  2023cites this paper
• Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines

  2023cites this paper
• Computational modeling of cyanobacterial phytoconstituents against toll-like receptors of skin cancer

  2023cites this paper
• Immunoinducible Carbon Dot-Incorporated Hydrogels as a Photothermal-Derived Antigen Depot to Trigger a Robust Antitumor Immune Response.

  2023cites this paper
• Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model

  2022cites this paper
• Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy

  2022cites this paper
• Stem-like T cells and niches: Implications in human health and disease

  2022cites this paper
• Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer

  2022cites this paper
• Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma.

  2022cites this paper
• The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling

  2022cites this paper
• Establishment of a lncRNA-Based Prognostic Gene Signature Associated With Altered Immune Responses in HCC

  2022cites this paper
• Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.

  2022cites this paper
• A Potent Micron Neoantigen Tumor Vaccine GP‐Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models

  2022cites this paper
• An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives

  2022cites this paper
• Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

  2022cites this paper
• Dendritic cells direct circadian anti-tumour immune responses

  2022cites this paper
• Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

  2022cites this paper
• Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

  2021cites this paper
• Determining the Role of TLR Agonists in T Cell-Based Cancer Therapy

  2021cites this paper
• DNA Vaccines: Methods and Protocols

  2021cites this paper
• Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

  2021cites this paper
• A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer

  2021cites this paper
• Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines

  2021cites this paper
• Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

  2021cites this paper
• Cancer vaccines: translational strategies

  2021cites this paper
• Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials

  2021cites this paper
• The next generation of HCV vaccines: a focus on novel adjuvant development

  2021cites this paper
• Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates.

  2021cites this paper
• Combining nonsense-mediated mRNA decay inhibition and personalized vaccine to target new frame-derived tumor antigens By SHREYA GANDHI A thesis submitted to the School of Graduate Studies

  2021cites this paper
• Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

  2021cites this paper
• Vaccines targeting angiogenesis in melanoma.

  2021cites this paper
• Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model

  2021cites this paper
• Nano-Medicines a Hope for Chagas Disease!

  2021cites this paper
• Towards customized cancer vaccines: a promising filed in personalized cancer medicine

  2021cites this paper
• Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors

  2021cites this paper
• B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity

  2021cites this paper
• Therapeutic cancer vaccines

  2021cites this paper
• Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants

  2021cites this paper
• Helicase antigen (HAGE)‐derived vaccines induce immunity to HAGE and ImmunoBody®‐HAGE DNA vaccine delays the growth and metastasis of HAGE‐expressing tumors in vivo

  2021cites this paper
• CpG-Based Nanovaccines for Cancer Immunotherapy

  2021cites this paper
• CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses

  2020cites this paper
• Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future

  2020cites this paper
• Dendritic cells in the tumor microenvironment: prognostic and theranostic impact.

  2020cites this paper
• Toll-Like Receptor 9 Agonists in Cancer

  2020cites this paper
• A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control

  2020cites this paper
• CpG Oligonucleotides as Vaccine Adjuvants.

  2020cites this paper
• Immune profiling before treatment is predictive of TLR9-induced antitumor efficacy.

  2020cites this paper
• The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8+ T-cell responses in vitro

  2020cites this paper
• Modulation of immune responses using adjuvants to facilitate therapeutic vaccination

  2020cites this paper
• The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice

  2020cites this paper
• Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants

  2020cites this paper
• Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses

  2020cites this paper
• A Minority of T Cells Recognizing Tumor-Associated Antigens Presented in Self-HLA Can Provoke Anti-Tumor Reactivity.

  2020cites this paper
• The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies

  2020cites this paper
• An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

  2020cites this paper
• Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints

  2020cites this paper
• Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

  2020cites this paper
• Modeling the Dependence of Immunodominance on T Cell Dynamics in Prime-Boost Vaccines

  2020cites this paper
• Arming the melanoma sentinel lymph node against metastatic spread : Translational studies on early adjuvant therapy of melanoma by intradermal administration of dendritic cell targeting agents CpG-B and GM-CSF

  2020cites this paper
• High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence

  2020cites this paper
• OTT_A_247050 10039..10060

  2020cites this paper
• Opportunities for Small Molecules in Cancer Immunotherapy.

  2020cites this paper
• Interrogating the recognition landscape of a conserved HIV-specific TCR reveals distinct bacterial peptide cross-reactivity

  2020influential citation
• Advances in nanocarriers as drug delivery systems in Chagas disease

  2019cites this paper
• Nucleic acids presenting polymer nanomaterials as vaccine adjuvants.

  2019cites this paper
• Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial

  2019cites this paper
• Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication

  2019cites this paper
• Vaccine Strategy in Melanoma.

  2019cites this paper
• Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses

  2019cites this paper
• Vaccination with nanoparticles combined with micro-adjuvants protects against cancer

  2019cites this paper
• A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

  2019cites this paper
• Innate sensors that regulate vaccine responses.

  2019cites this paper
• Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)—Mediated Anti-tumor Therapy

  2019cites this paper
• Anticancer Immunotherapy: Prospects and Challenges

  2019cites this paper
• Improving Cancer Vaccine Efficiency by Nanomedicine

  2019cites this paper
• Impact of TCR-ligand avidity for viral and tumor antigens on human CD8 T cell potency and long-term persistence

  2019cites this paper
• Virus-like particles in der Prophylaxe und Immuntherapie allergischer Erkrankungen

  2018cites this paper
• CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response

  2018cites this paper
• Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases

  2018cites this paper
• Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C)

  2018cites this paper